Autoimmune haemolytic anaemia emerging during Campath treatment in a patient with CD5 negative chronic lymphocytic leukaemia

• DOI: 10.1007/s12288-013-0239-2
• Publication Date: 2013-02-11T06:11:40Z
• Authors: Paul R. J. Ames; Darren Aw; Mervin G. Rainey
• Keywords: CD5; Hematology

Campath is being employed for the treatment of autoimmune haemolytic anemia (AIHA) whether or not associated to B cell chronic lymphoid leukaemia (CLL). CD5 negative CLL is relatively uncommon and runs an indolent course. We report a CD5 negative CLL patient who developed AIHA associated with cytomegalovirus infection reactivation whilst on treatment with Campath for progressive disease.